



22 December 2016

#### **Controlled Placement Agreement and Cleansing Notice**

Inca Minerals Limited (Inca or Company) is pleased to advise it has renewed its Controlled Placement Agreement (CPA) with Acuity Capital Investment Management Pty Ltd (Acuity) (previously announced 25 March 2015 and 14 November 2016). As collateral for renewal of the CPA, Inca has agreed to place 70,000,000 fully paid ordinary shares from its ASX 7.1 (15%) capacity, at nil consideration, to Acuity (Collateral Shares) but Inca may, at any time, cancel the CPA and buy back the Collateral Shares for nil consideration (subject to shareholder approval).

Inca retains sole discretion as to whether the CPA is utilised and, in the event of a placement, the minimum issue price. The Board believes the CPA renewal is advantageous, prudent and consistent with maintaining funding options and strengthening the Company's capital management capacity. Inca's Managing Director, Mr Ross Brown said "Historically, the CPA has proved highly effective and meant Inca's placements through Acuity have been achieved without the usual broker management costs and at a premium to or at market price. Inca is very pleased to have again reached agreement with Acuity and to have the CPA as part of our exploration funding options."

Other key features of the CPA include:

- No obligation on Inca to utilise the CPA facility and no penalty or fees if Inca elects not to utilise or cancel the CPA facility.
- Providing Inca with a discretionary option of using the CPA to raise up to \$A3 million without restriction
  or conditions on strategic partnerships, joint ventures, acquisitions of any assets or on the timing,
  nature or amount of any other equity or debt funding mechanisms.
- In the event of a placement, Inca retains the ability to determine:
  - The placement period being the date(s) over which the volume weighted average price (VWAP) and placement price are calculated;
  - Maximum placement amount to be issued for any placement period thereby minimising dilution of existing shareholders; and
  - The minimum issue price for the placement period.
- Use of the CPA facility is dependent upon Inca's available placement capacity under ASX Listing Rules.

The requisite Appendix 3B for the Collateral Shares (referred to above) is attached to this announcement.

Inca provides the following information pursuant to ASX Listing Rule 3.10.5 and Section 708A(5)(e) of the Corporations Act.





The Collateral Shares (referred to above) were issued without disclosure to Acuity under Part 6D.2 of the Corporations Act and using Inca's share placement capacity pursuant to ASX Listing Rule 7.1.

As at the date of this notice Inca has complied with:

- (a) The provisions of Chapter 2M of the Corporations Act;
- (b) Section 674 of the Corporations Act; and

there is no excluded information for the purposes of Sections 708A(7) and (8) of the Corporations Act.

Justin Walawski **Director & Company Secretary** 

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/oo, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$ 

1. 5. 5		
Name o	of entity	
Inca I	Minerals Limited	
ABN		
128 51	12 907	
We (t	he entity) give ASX the following	information.
Part	1 - All issues	
You mu	ust complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares.
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	70,000,000
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares ranking equally with all other issued ordinary shares and on the terms and conditions set out in ASX announcements 22 December 2017 and 14 November 2016.

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes.
5	Issue price or consideration	Nil. Shares are issued as collateral for the renewal of a Controlled Placement Agreement with Acuity Capital as announced 22 December 2017.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	See above.
ба	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6с	Number of *securities issued without security holder approval under rule 7.1	70,000,000
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6е	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	Nil	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A.	
6h	If *securities were issued under	N/A.	
	rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	,	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Remaining Issue Capacity	Rule 7.1: 269,512,569
7	<sup>+</sup> Issue dates	22 December 2017	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	22 December 2017	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	2,563,316,197	Fully paid ordinary shares.
		<b>N</b> T 1	
9	Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	Number Nil	+Class N/A

<sup>+</sup> See chapter 19 for defined terms.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Rank equally from issue date with all existing quoted fully paid ordinary shares.

#### Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
Names	of any underwriters	N/A
Amour	nt of any underwriting fee or	N/A

20

21

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

22	Name	s of any brokers to the issue	N/A
	_		
23	fee or to the	commission payable to the broker issue	N/A
			N/A
24	broke	ant of any handling fee payable to rs who lodge acceptances or ciations on behalf of security rs	N/A
25		rissue is contingent on security rs' approval, the date of the ng	N/A
26	Dato	entitlement and acceptance form	N/A
26	and o	offer documents will be sent to ns entitled	N/A
	T.C. 1		Lista
27	terms partic	ipate on exercise, the date on notices will be sent to option	N/A
28	Date applic	rights trading will begin (if able)	N/A
29	Date applic	rights trading will end (if able)	N/A
30		do security holders sell their ements in full through a broker?	N/A
		Have do consuity haldows call want	NIΔ
	31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
	32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
	33	<sup>+</sup> Issue date	N/A

<sup>+</sup> See chapter 19 for defined terms.

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type (tick o	of <sup>+</sup> securities one)
(a)	$\overline{\checkmark}$	*Securities described in Part 1
(b)		All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities.

#### Entities that have ticked box 34(a)

documents

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or

If the \*securities are \*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders

If the \*securities are \*equity securities, a distribution schedule of the additional

\*securities setting out the number of holders in the categories

1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000

100,001 and over

37 A copy of any trust deed for the additional \*securities

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Entities that have ticked box 34(b)			
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify		
	that other <sup>+</sup> security)	Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)		

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 22 December 2017

(Director/Company secretary)

Print name: Justin Walawski

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	2,239,444,757	
Add the following:  Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	160,611,625 (issued 12 December 2017 under a non-renounceable pro-rata entitlement offer).	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	46,800,000 (Issued 9 February 2017. Shareholder approval at AGM 29 November 2016).	
	18,212,110 shares (issued 6 July 2017. Shareholder approval at AGM 29 November 2016).	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
Subtract the number of fully paid  +ordinary securities cancelled during that 12 month period	0	
"A"	2,465,068,492	

<sup>+</sup> See chapter 19 for defined terms.

Cton 2: Coloulate 450/ of "A"		
Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	369,760,274	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:	100,247,705	
• Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	100,247,705	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	369,760,274	
Note: number must be same as shown in Step 2		
Subtract "C"	100,247,705	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	269,512,569	
	1	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	N/A	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<ul> <li>Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>		
"E"		

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.